SynthesisCancer immunology, immunotherapy : CII2022

Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.

Hui Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.